<DOC>
	<DOCNO>NCT00084981</DOCNO>
	<brief_summary>This phase I trial study side effect best dose decitabine valproic acid treat patient non-small cell lung cancer . Drugs use chemotherapy , decitabine valproic acid , work different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell .</brief_summary>
	<brief_title>Decitabine Valproic Acid Treating Patients With Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine safety tolerability decitabine valproic acid patient non-small cell lung cancer . II . Determine recommend phase II dose regimen patient . SECONDARY OBJECTIVES : I . Determine ability regimen lead biological change tumor surrogate tissue patient , include hypomethylation target gene know methylated NSCLC ( CDKN2 , APC , BMP3B , CDH1 RASSF1A ) biopsy specimen surrogate tissue ( peripheral blood mononuclear cell [ PBMC ] plasma/serum DNA ) ; acetylation methylation change histone tumor surrogate tissue ( PBMC oral epithelial cell ) ; inhibition histone deacetylase ( HDAC ) activity peripheral blood ; pharmacokinetic analysis Decitabine Valproic Acid ; DNA methyltransferase 1 ( DNMT1 ) protein loss PBMC buccal cell ; response hemoglobin F patient non-hematologic condition DNMT HDAC inhibition ; preliminary evidence antitumor activity non-small cell lung cancer . OUTLINE : This dose-escalation study . Patients receive decitabine IV 1 hour day 1-10 oral valproic acid three time daily day 5-21 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos decitabine valproic acid maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . After MTD determine , additional 6 patient treat dose .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Histologically cytologically confirm nonsmall cell lung cancer Tumor accessible biopsy bronchoscopy , surface biopsy ( e.g. , skin punch biopsy skin/subcutaneous metastasis ) CT scan guidance Not eligible curative surgery , chemotherapy , radiotherapy , multimodality treatment option No uncontrolled brain metastasis Controlled brain metastasis allow provided patient neurologic deterioration steroid ; complete prior radiotherapy treatment ; fully recover prior treatment ; require anticonvulsant Performance status ECOG 02 Performance status Karnofsky 60100 % More 12 week Absolute neutrophil count &gt; 1,500/mm^3 Platelet count &gt; 100,000/mm^3 WBC &gt; 3,000/mm^3 AST ALT = &lt; 2.5 time upper limit normal ( ULN ) Bilirubin = &lt; 1.5 time ULN Creatinine = &lt; 1.5 time ULN Creatinine clearance &gt; = 60 mL/min No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior allergic reaction compound similar chemical biological composition decitabine , valproic acid , study agent No concurrent uncontrolled illness No ongoing active infection require antibiotic No history seizures require anticonvulsant No medical problem would preclude study participation No psychiatric illness social situation would preclude study compliance No active malignancy except nonmelanoma skin cancer carcinoma situ cervix No concurrent prophylactic growth factor ( e.g. , filgrastim [ GCSF ] epoetin alfa ) No 3 prior chemotherapy regimens More 3 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover Prior definitive radiotherapy chest allow Clinical ( radiographic ) evidence tumor progression previously irradiate indicator lesion chest More 2 week since prior radiotherapy recover No concurrent palliative radiotherapy Prior curative palliative intent surgery allow At least 2 week since prior surgery recover At least 4 week since prior photodynamic therapy No concurrent combination antiretroviral therapy HIVpositive patient No concurrent anticancer agent therapies No concurrent investigational agent No concurrent administration follow medication : Aspirin Chronic lowdose ( = &lt; 81 mg/day ) aspirin allow Felbamate Rifampin Amitriptyline Nortriptyline Carbamazepine Clonazepam Diazepam Ethosuximide Lamotrigine Phenobarbital Barbiturates Primidone Phenytoin Zidovudine No concurrent divalproex sodium Concurrent gabapentin neuropathic pain allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>